Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 33, Issue 5, 2012, Pages 386-396

  Van Bavel, Julius H ^a   Ratner, Paul H ^b   Amar, Niran J ^c   Hampel, Frank C ^d   Melchior, Amy ^e   Dunbar, Stephanie A ^e   Dorinsky, Paul M ^e   Tantry, Sudeesh K ^e  

^a Transplicegen Therapeutics   (United States)

^b Sylvana Research Associates   (United States)

^c Allergy and Asthma Center PA   (United States)

^d Central Texas Allergy and Asthma   (United States)

^e Teva Branded Pharmaceutical Products R and D Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; PLACEBO;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HAY FEVER; HUMAN; HYPERTENSIVE CRISIS; MAJOR CLINICAL STUDY; MALE; NASAL DISCOMFORT; NAUSEA; NOSE DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; STEROID THERAPY; URTICARIA;

EID: 84866759046     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3593     Document Type: Article

References (25)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008. (Pubitemid 352033573)
2. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108(suppl 1):S2-S8, 2001.
3. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
4. Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. Lancet 378:2112-2122, 2011.
5. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
6. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998. (Pubitemid 28554544)
7. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100:272-279, 2008. (Pubitemid 351398007)
8. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis. Allergy Asthma Proc 32:168-177, 2011.
9. Fromer LM, Ortiz G, Ryan SF, et al. Insights on allergic rhinitis from the patient perspective. J Fam Pract 61(suppl):S16-S22, 2012.
10. Naclerio RM, Hadley JA, Stoloff S, et al. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28:S11-S17, 2007.
11. GlaxoSmithKline. Beconase AQ (beclomethasone dipropionate, monohydrate) nasal spray package insert. Research Triangle Park, NC; April 2005.
12. Montreal Protocol. Available online at www.epa.gov/ozone/intpol/; accessed March 13, 2012.
13. Teva Respiratory, LLC. QVAR 40 μg (beclomethasone dipropionate HFA, 40 μg) inhalation aerosol for oral inhalation only; QVAR 80 μg (beclomethasone dipropionate HFA, 80 μg) inhalation aerosol for oral inhalation only package insert. Frazer, PA; September 2010.
14. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996. (Pubitemid 26357253)
15. Kim K, Weiswasser M, and Nave R. Safety of once-daily ciclesonide nasal spray in children 2 to 5 years of age with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol 20:229-249, 2007.
16. Barnes ML, Vaidyanathan S, Williamson PA, et al. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy 40:242-250, 2010.
17. Meltzer EO, Jacobs RL, LaForce CF, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 33:249-257, 2012.
18. Blaiss MS. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: Role of intranasal corticosteroids. Curr Med Res Opin 24:821-836, 2008. (Pubitemid 351428994)
19. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007. (Pubitemid 46855849)
20. Ratner PH, Melchior A, Dunbar SA, et al. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. Clin Ther 34:1422-1431, 2012.
21. Ratner PH, Miller SD, Hampel FC, et al. BDP HFA nasal aerosol 320 μg once daily is not associated with HPA axis suppression in subjects with perennial allergic rhinitis. Ann Allergy Asthma Immunol 107(suppl B1-B2):A118, Abstract P358, 2011.
22. Hampel FC, Ratner PH, Miller SD, et al. Once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg/d) is not associated with hypothalamic-pituitary-adrenal axis suppression in adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol 129(suppl):AB188, 2012.
23. Nayak AS, Andrews CP, Bernstein DI, et al. Long-term (52-week) treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg once daily) is safe and effective in adult and adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol 129(suppl):AB189, 2012.
24. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:E23, 2000.
25. Segall N, Mansfield L, Amar N, et al. Once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol is safe and effective in children (6-11 years of age) with seasonal allergic rhinitis. J Allergy Clin Immunol 129(suppl): AB188, 2012.